Lilly (Eli) vs Trimble Ag Software

Side-by-side comparison of AI visibility scores, market position, and capabilities

Trimble Ag Software leads in AI visibility (95 vs 88)
Lilly (Eli) logo

Lilly (Eli)

LeaderHealthcare Tech

Enterprise

Indianapolis pharma leader (NYSE: LLY) $45.1B FY2024 revenue (+32%); Mounjaro $11.4B + Zepbound $4.9B tirzepatide GLP-1, oral orforglipron Phase 3, $18B manufacturing expansion competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A88
Category Rank
#125 of 290
AI Consensus
51%
Trend
stable
Per Platform
ChatGPT
89
Perplexity
79
Gemini
99

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Health Care component — discovering, developing, and commercializing medicines across diabetes, obesity, oncology, immunology, and neuroscience through approximately 43,000 employees worldwide. In fiscal year 2024, Eli Lilly reported revenues of $45.1 billion (+32% year-over-year) — driven by the historic commercial launch of Mounjaro (tirzepatide for type 2 diabetes, $11.4B revenue) and Zepbound (tirzepatide for obesity and obstructive sleep apnea, $4.9B revenue) — making Eli Lilly one of the fastest-growing large pharmaceutical companies in history and elevating its market capitalization above $700 billion at peak 2024 valuation, briefly making Lilly the most valuable healthcare company globally. CEO Dave Ricks' strategic investment in tirzepatide manufacturing capacity — committing $18+ billion to new US manufacturing sites in Indiana, Wisconsin, and North Carolina — reflects Lilly's execution of unprecedented pharmaceutical demand that has consistently outpaced supply since Mounjaro's 2022 approval and Zepbound's 2023 FDA approval for obesity. The GLP-1/GIP dual agonist mechanism (tirzepatide activates both GLP-1 and GIP incretin receptors, versus semaglutide's single GLP-1 activation) produces superior efficacy results — SURMOUNT-1 trial showing 22.5% average body weight loss with tirzepatide versus 15% with semaglutide (Ozempic/Wegovy) — establishing tirzepatide as the most effective approved obesity pharmacotherapy.

Full profile
Trimble Ag Software logo

Trimble Ag Software

LeaderAgriculture

Precision Agriculture

Trimble (NASDAQ: TRMB) precision agriculture software with GPS guidance and variable rate application for farm management; competing with John Deere Operations Center and Climate FieldView for crop data platform.

AI VisibilityBeta
Overall Score
A95
Category Rank
#2 of 4
AI Consensus
92%
Trend
stable
Per Platform
ChatGPT
95
Perplexity
93
Gemini
94

About

Trimble Ag Software is the precision agriculture software division of Trimble Inc. (NASDAQ: TRMB) — a Sunnyvale, California-based positioning and workflow technology company with $3.7 billion in annual revenue — providing farmers, agronomists, and farm managers with field mapping, GPS-guided variable rate application, crop record management, and agronomic analytics that enable data-driven farming decisions across planting, spraying, harvesting, and soil management. Operating under the Trimble Agriculture brand with products including Trimble TMX-2050, Trimble Farmer Core/Pro/Premium, and the Trimble Connected Farm suite, the division serves large-scale crop producers and ag service providers in North America, Europe, and Australia.

Full profile

AI Visibility Head-to-Head

88
Overall Score
95
#125
Category Rank
#2
51
AI Consensus
92
stable
Trend
stable
89
ChatGPT
95
79
Perplexity
93
99
Gemini
94
90
Claude
96
80
Grok
96

Key Details

Category
Enterprise
Precision Agriculture
Tier
Leader
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only Trimble Ag Software
Precision Agriculture

Integrations

Only Lilly (Eli)
Lilly (Eli) is classified as company. Trimble Ag Software is classified as company (part of Trimble Agriculture).

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.